Ignite Creation Date:
2024-05-06 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05266846
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2022-02-18
Brief Title:
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5ALK
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Organization Data
Organization:
Hunan Province Tumor Hospital
Class:
OTHER
Study ID:
2022017
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hunan Province Tumor Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Yongchang Zhang
Responsible Party Title:
Professor Deputy Director of Thoracic Oncology Department
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Hunan Province Tumor Hospital
Old Name:
None
Old Organization:
None